229 related articles for article (PubMed ID: 19276287)
1. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.
Magnifico A; Albano L; Campaner S; Delia D; Castiglioni F; Gasparini P; Sozzi G; Fontanella E; Menard S; Tagliabue E
Clin Cancer Res; 2009 Mar; 15(6):2010-21. PubMed ID: 19276287
[TBL] [Abstract][Full Text] [Related]
2. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
3. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
5. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
[TBL] [Abstract][Full Text] [Related]
7. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
10. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.
Wen XF; Yang G; Mao W; Thornton A; Liu J; Bast RC; Le XF
Oncogene; 2006 Nov; 25(52):6986-96. PubMed ID: 16715132
[TBL] [Abstract][Full Text] [Related]
11. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
12. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
13. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
du Manoir JM; Francia G; Man S; Mossoba M; Medin JA; Viloria-Petit A; Hicklin DJ; Emmenegger U; Kerbel RS
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):904-16. PubMed ID: 16467105
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
[TBL] [Abstract][Full Text] [Related]
16. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts.
Baker JH; Lindquist KE; Huxham LA; Kyle AH; Sy JT; Minchinton AI
Clin Cancer Res; 2008 Apr; 14(7):2171-9. PubMed ID: 18381959
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
[TBL] [Abstract][Full Text] [Related]
18. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.
Ciravolo V; Huber V; Ghedini GC; Venturelli E; Bianchi F; Campiglio M; Morelli D; Villa A; Della Mina P; Menard S; Filipazzi P; Rivoltini L; Tagliabue E; Pupa SM
J Cell Physiol; 2012 Feb; 227(2):658-67. PubMed ID: 21465472
[TBL] [Abstract][Full Text] [Related]
19. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
Matsui Y; Inomata M; Tojigamori M; Sonoda K; Shiraishi N; Kitano S
Int J Oncol; 2005 Sep; 27(3):681-5. PubMed ID: 16077916
[TBL] [Abstract][Full Text] [Related]
20. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.
Dhillon J; Astanehe A; Lee C; Fotovati A; Hu K; Dunn SE
Oncogene; 2010 Nov; 29(47):6294-300. PubMed ID: 20802512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
